Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System
المؤلفون المشاركون
Wu, Bin
Bai, Yongrui
Xu, Yuejuan
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2017، العدد 2017 (31 ديسمبر/كانون الأول 2017)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2017-11-26
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objective.
This study evaluated the cost-effectiveness of apatinib in patients with chemotherapy-refractory mGC.
Patients and Methods.
A Markov model was developed to simulate the clinical course of typical patients with chemotherapy-refractory metastatic gastric cancer (mGC).
We estimated the 10-year quality-adjusted life-years (QALY), costs, and incremental cost-effectiveness ratios (ICER).
Model inputs were derived from the published literature and government sources.
Direct costs were estimated from the perspective of the Chinese health insurance system.
A scenario analysis for a Patient Assistance Programme (PAP) was performed.
Results.
Baseline analysis showed that apatinib increased the cost and QALYs by $7859 and 0.192, respectively, relative to conventional chemotherapy, resulting in an ICER of $40,997/QALY gained.
When PAP was available, the ICER was $21,132/QALY.
Probabilistic sensitivity analyses confirmed that apatinib with PAP achieved nearly 65% likelihood of cost-effectiveness at the threshold of $22,200.
One-way sensitivity analyses demonstrated that the utility of progression-free survival was the most influential factor on the robustness of the model.
Budget impact analysis estimated that the annual increase in fiscal expenditures would be approximately 0.45 million dollars.
Conclusions.
Our analysis suggests that apatinib is likely cost-effective in patients with chemotherapy-refractory mGC when PAP is available.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bai, Yongrui& Xu, Yuejuan& Wu, Bin. 2017. Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. Gastroenterology Research and Practice،Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1156286
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Bai, Yongrui…[et al.]. Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. Gastroenterology Research and Practice No. 2017 (2017), pp.1-7.
https://search.emarefa.net/detail/BIM-1156286
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bai, Yongrui& Xu, Yuejuan& Wu, Bin. Cost-Effectiveness and Budget Impact Analysis of Apatinib for Advanced Metastatic Gastric Cancer from the Perspective of Health Insurance System. Gastroenterology Research and Practice. 2017. Vol. 2017, no. 2017, pp.1-7.
https://search.emarefa.net/detail/BIM-1156286
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1156286
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر